

Akshay K Gupta, Ajay Gupta, Ajay K

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/386593/publications.pdf>

Version: 2024-02-01

52
papers

2,422
citations

393982

19
h-index

233125

45
g-index

53
all docs

53
docs citations

53
times ranked

4058
citing authors

#	ARTICLE	IF	CITATIONS
1	Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. Hypertension, 2010, 55, 399-407.	1.3	579
2	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324â€™168 participants from randomised trials. Lancet Oncology, The, 2011, 12, 65-82.	5.1	332
3	Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trialâ€™Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet, The, 2017, 389, 2473-2481.	6.3	279
4	Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Journal of Hypertension, 2011, 29, 2004-2013.	0.3	147
5	Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trialâ€™Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication. Diabetes Care, 2008, 31, 982-988.	4.3	142
6	The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. European Heart Journal, 2011, 32, 2525-2532.	1.0	110
7	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet, The, 2018, 392, 1127-1137.	6.3	87
8	Role of phytosterols in lipid-lowering: current perspectives. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 301-308.	0.2	85
9	The Efficacy and Tolerability of â€™Polypillsâ€™™: Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2012, 7, e52145.	1.1	74
10	Ethnic Differences in Blood Pressure Response to First and Second-Line Antihypertensive Therapies in Patients Randomized in the ASCOT Trial. American Journal of Hypertension, 2010, 23, 1023-1030.	1.0	72
11	Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500,000 patients with Type 2 diabetes mellitus. European Heart Journal, 2019, 40, 2899-2906.	1.0	59
12	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncology, The, 2021, 22, 558-570.	5.1	56
13	Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the <i>JAHA</i> Editors. Journal of the American Heart Association, 2020, 9, e017013.	1.6	52
14	COVID-19: Causes of anxiety and wellbeing support needs of healthcare professionals in the UK: A cross-sectional survey. Clinical Medicine, 2021, 21, 66-72.	0.8	41
15	Over 1000 genetic loci influencing blood pressure with multiple systems and tissues implicated. Human Molecular Genetics, 2019, 28, R151-R161.	1.4	39
16	Metabolic Syndrome, Independent of Its Components, Is a Risk Factor for Stroke and Death But Not for Coronary Heart Disease Among Hypertensive Patients in the ASCOT-BPLA. Diabetes Care, 2010, 33, 1647-1651.	4.3	37
17	Antral resection versus antral preservation during laparoscopic sleeve gastrectomy for severe obesity: Systematic review and meta-analysis. Surgery for Obesity and Related Diseases, 2018, 14, 857-864.	1.0	37
18	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology, 2017, 106, 58-68.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14â€¦120 hypertensive patients of ASCOTâ€¦BPLA: comparison of their relative predictability using a novel approach. Diabetic Medicine, 2011, 28, 941-947.	1.2	20
20	Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). European Heart Journal, 2012, 33, 2970-2979.	1.0	14
21	ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. Journal of Human Hypertension, 2013, 27, 492-496.	1.0	14
22	Malignant Hypertension: Current Perspectives and Challenges. Journal of the American Heart Association, 2022, 11, e023397.	1.6	14
23	Implementation of depression screening in antenatal clinics through tablet computers: results of a feasibility study. BMC Medical Informatics and Decision Making, 2017, 17, 59.	1.5	13
24	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. Journal of the American Heart Association, 2018, 7, .	1.6	13
25	Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. American Journal of Cardiovascular Drugs, 2019, 19, 313-323.	1.0	9
26	Early and Mid-Term Implications of the COVID-19 Pandemic on the Physical, Behavioral and Mental Health of Healthcare Professionals: The CoPE-HCP Study Protocol. Frontiers in Psychology, 2021, 12, 616280.	1.1	7
27	Long-Term Incidence of Stroke and Dementia in ASCOT. Stroke, 2021, 52, 3088-3096.	1.0	7
28	Tablet computers for implementing NICE antenatal mental health guidelines: protocol of a feasibility study. BMJ Open, 2016, 6, e009930.	0.8	6
29	COVID-19 and the Digitalisation of Cardiovascular Training and Educationâ€¦A Review of Guiding Themes for Equitable and Effective Post-graduate Telelearning. Frontiers in Cardiovascular Medicine, 2021, 8, 666119.	1.1	6
30	<i>JAHA</i> Spotlight on Air Pollution and Cardiovascular Disease: A Call for Urgent Action. Journal of the American Heart Association, 2021, 10, e022209.	1.6	5
31	Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide. British Journal of Pharmacology, 2022, 179, 4757-4777.	2.7	5
32	Pollutants Source Control and Health Effects. Journal of Environmental and Public Health, 2013, 2013, 1-2.	0.4	4
33	Solar UV Radiation: A Potential Modifiable Risk Factor for Hypertension. Journal of the American Heart Association, 2020, 9, e015627.	1.6	4
34	LONG TERM BENEFITS OF BLOOD PRESSURE TREATMENT ON THE INCIDENCE OF ATRIAL FIBRILLATION, HEART FAILURE AND CARDIOVASCULAR MORBIDITY AND MORTALITY: 20-YEARS FOLLOW-UP OF ASCOT-LEGACY. Journal of Hypertension, 2021, 39, e8.	0.3	4
35	Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patients. Journal of Hypertension, 2022, 40, 1522-1529.	0.3	4
36	The Concept of the Metabolic Syndrome. Journal of the American College of Cardiology, 2010, 56, 1355-1356.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Childhood Obesity: Today and Tomorrow's Health Challenge. <i>Journal of Obesity</i> , 2013, 2013, 1-2.	1.1	3
38	Equity, Diversity, and Inclusiveness in Cardiovascular Medicine and Health Care. <i>Journal of the American Heart Association</i> , 2020, 9, e019137.	1.6	3
39	The efficacy and cost-effectiveness of statins in low-risk patients. <i>Cmaj</i> , 2011, 183, 1821-1823.	0.9	2
40	LBOS 01-04 THE TRUE INCIDENCE OF STATIN -RELATED ADVERSE EVENTS IN HYPERTENSIVE PATIENTS REVEALED BY COMPARISON OF BLINDED AND UN-BLINDED USE OF STATIN IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT). <i>Journal of Hypertension</i> , 2016, 34, e547-e548.	0.3	2
41	Concerns related to the nocebo effect – Authors' reply. <i>Lancet</i> , The, 2017, 390, 1832.	6.3	2
42	Impact of the New ACC/AHA and ESC/ESH Hypertension Guidelines in the UK. <i>European Heart Journal</i> , 2019, 40, 2472-2475.	1.0	2
43	THE RELATIONSHIP BETWEEN BP-CONTROL, BP -VARIABILITY AND ANTIHYPERTENSIVE TREATMENT WITH THE LONG-TERM RISK OF CARDIOVASCULAR EVENT: LESSONS FROM THE ASCOT-LEGACY 20 YEAR FOLLOW-UP. <i>Journal of Hypertension</i> , 2021, 39, e148.	0.3	2
44	Antihypertensive-Associated Incident Diabetes: Controversy Persists. <i>Archives of Internal Medicine</i> , 2007, 167, 1433.	4.3	1
45	Hypertensive Disorders in Pregnancy and the Risk of Cardiovascular Disease: A Need for Postpartum Strategies for the Primary Prevention. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	1
46	Diversity, Equity, and Inclusiveness in Medicine and Cardiology: Next Steps for JAHA. <i>Journal of the American Heart Association</i> , 2020, 9, e019307.	1.6	1
47	Improving the Prognosis in Patients With Diabetes: What Will ADVANCE Tell Us?. <i>American Journal of Hypertension</i> , 2007, 20, S19-S22.	1.0	0
48	A17615 Baseline predictors of all-cause- and cardiovascular- mortality amongst 8580 hypertensive patients followed up for 16 years in the ASCOT legacy study. <i>Journal of Hypertension</i> , 2018, 36, e251.	0.3	0
49	COMPARING THE DISCRIMINATIVE ABILITY OF DIFFERENT ELECTROGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY IN PREDICTING CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS. <i>Journal of Hypertension</i> , 2021, 39, e165-e166.	0.3	0
50	INFLUENCE OF AGE, SEX AND AN OCCURRENCE OF CARDIOVASCULAR EVENT ON SEASONAL VARIATIONS IN BLOOD PRESSURES IN HYPERTENSIVE PATIENTS: INSIGHTS FROM THE ASCOT COHORT. <i>Journal of Hypertension</i> , 2021, 39, e145-e146.	0.3	0
51	THE DEVELOPMENT OF RESISTANT HYPERTENSION INDEPENDENT OF THE PRECEDING PERIOD OF THE BLOOD PRESSURE CONTROL IS ASSOCIATED WITH THE INCREASED RISK OF CARDIOVASCULAR EVENTS AND DEATH. <i>Journal of Hypertension</i> , 2021, 39, e358.	0.3	0
52	Blood Pressure – Lowering Effects of Omega-3 Polyunsaturated Fatty Acids: Are These the Missing Link to Explain the Relationship Between Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Disease?. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	0